ABCD is pleased to announce the updated guidance on SGLT-2 inhibitors in type 2 diabetes. SGLT-2 inhibitors are being used increasingly not only for better diabetes control with less risk of hypoglycaemia and favourable weight loss, but also for their cardiovascular and renal benefits in people with and without diabetes. It is hoped that the updated guidance will help non-specialists to use SGLT-2 inhibitors safely and in the right patients for maximum benefit.

Access guidance.

Two of the core objectives of the Association of British Clinical Diabetologists (ABCD) are to ensure the highest quality of care for people with diabetes and to provide a resource of information; not only for our members but also the wider multidisciplinary team and colleagues providing care for people with diabetes.

Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes.

Authors:

Piya Sen Gupta, Stephanie Armstrong, Stephanie A. Amiel, Robert E. Ryder, Mark W. Pennington.

The Diabetes Technology Network UK (DTN-UK) are looking for an experienced diabetes educator (dietitian, DSN or other HCP) to join the committee of DTN-UK, part of the Association of British Clinical Diabetologists (ABCD).

DTN-UK is an organisation which exists to support UK health care professionals involved in using technology designed to improve the lives of people living with diabetes.

UK first National Health Service (NHS) Endobarrier Service for uncontrolled DIABESITY shows the metabolic improvements 6-months after Endobarrier removal are well maintained.

Authors:

REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta.

Impact of Endobarrier on need for continuous-positive-airway-pressure ventilation (CPAP) in diabetes/pre-diabetes with obstructive sleep apnoea (OSA) study: current data at Endobarrier removal and 6-months later.

Authors:

M Yadagiri, F Kinney, J Adams, N. Ashman, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder.

Duodenal jejunal bypass liner for DIABESITY - Risk Versus benefit data from the Association of British Clinical Diabetologists (ABCD) Worldwide Endobarrier Registry.

Authors:

B. Ryder, M. Lynne, H. Frydenberg, S. Fishman, R. Cohen, C. de Jonge, J. Greve, J. Bascomb, J. Bessell, J. McMaster, G. Holtman, G. Rich, J. Collins, L. Kow, P. Pferschy, H. Sourij, J. Byrne, J. Mason, J. Teare, M. Benes.

Evaluation of the efficacy and safety of endoscopically achieved proximal intestinal exclusion as an adjunct to glucagon-like peptide-1  therapy in Diabesity: REVISE-DIABESITY randomised clinical trial.

Authors: 

P. Sen Gupta, B. McGowan, R. Drummond, S. Amiel, B. Ryder.

The 2023 National Clinical Impact Awards round is now open for applications.

Applications opened on Friday 10th March and will close at 5pm on Friday 5th May 2023.

Sodium-glucose link transporter-2 inhibitors in reduced renal function: Cross-class comparison from the Association of British Clinical Diabetologists (ABCD) audits.

Authors:

TSJ Crabtree, A Bickerton, K Dhatariya, A Gallagher, J Elliott, R Raghavan, IW Gallen, REJ Ryder on behalf of all ABCD SGLT2 audit contributors.